Mather Group
BBIO icon

Mather Group’s BridgeBio Pharma BBIO Stock Holding History

Mather Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.42K Buy
+52
New +$4.05K ﹤0.01% 1910
2025
Q4 		– Sell
-70
Closed -$3.64K – 743
2025
Q3 		$3.64K Buy
+70
New +$3.41K ﹤0.01% 1453

Other funds holding BBIO

Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Burney Company
Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Amalgamated Bank
Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Inspire Investing
Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return
FBT
First Bank & Trust Brookings, South Dakota $687M AUM 18.35% 1-Year Est. Return

Mather Group's BBIO Position: Q3 2026 in Review

Mather Group opened a new position in BridgeBio Pharma (BBIO) in Q3 2026: 52 shares worth $3.42K. The stake represents ﹤0.01% of the portfolio and ranks #1910 among its holdings. This is a return to the name: Mather Group previously reported a position in BBIO as recently as Q3 2025.

Mather Group first reported a position in BBIO in Q3 2025 and has held it in 2 quarters since. The position peaked at $3.64K in Q3 2025. 57 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • Mather Group held 52 shares of BridgeBio Pharma worth $3.42K as of Q3 2026.
  • BridgeBio Pharma was a new Mather Group position in Q3 2026.
  • BridgeBio Pharma made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1910 holding.
  • Mather Group first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 2 quarters since.
  • Mather Group's BridgeBio Pharma position peaked at $3.64K in Q3 2025.
  • 57 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.